Nano-structures mediated co-delivery of therapeutic agents for glioblastoma treatment: A review

被引：64

作者：

Mujokoro, Basil ^{[1
]}

Adabi, Mohsen ^{[2
]}

Sadroddiny, Esmaeil ^{[3
]}

Adabi, Mahdi ^{[4
]}

Khosravani, Masood ^{[4
]}

机构：

[1] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Med Nanotechnol, Int Campus, Tehran, Iran

[2] Islamic Azad Univ, Roudehen Branch, Young Researchers & Elite Club, Roudehen, Iran

[3] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Med Biotechnol, Tehran, Iran

[4] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Med Nanotechnol, Tehran, Iran

来源：

MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS | 2016年 / 69卷

关键词：

Glioblastoma; Co-delivery; Drug delivery; Nanoparticle; Chemotherapy; Chemosensitizer; Gene therapy; SOLID LIPID NANOPARTICLES; CONVECTION-ENHANCED DELIVERY; BEVACIZUMAB PLUS IRINOTECAN; GROWTH-FACTOR RECEPTOR; HUMAN SERUM-ALBUMIN; PHASE-II TRIAL; DRUG-DELIVERY; TEMOZOLOMIDE RESISTANCE; RECURRENT GLIOBLASTOMA; IN-VITRO;

D O I：

10.1016/j.msec.2016.07.080

中图分类号：

TB3 [工程材料学]; R318.08 [生物材料学];

学科分类号：

0805 ; 080501 ; 080502 ;

摘要：

Glioblastoma is a malignant brain tumor and leads to death in most patients. Chemotherapy is a common method for brain cancer in clinics. However, the recent advancements in the chemotherapy of brain tumors have not been efficient enough. With the advancement of nanotechnology, the used drugs can enhance chemotherapy efficiency and increase the access to brain cancers. Combination of therapeutic agents has been recently attracted great attention for glioblastoma chemotherapy. One of the early benefits of combination therapies is the high potential to provide synergistic effects and decrease adverse side effects associated with high doses of single anticancer drugs. Therefore, brain tumor treatments with combination drugs can be considered as a crucial approach for avoiding tumor growth. This review investigates current progress in nano-mediated co-delivery of therapeutic agents with focus on glioblastoma chemotherapy prognosis. (C) 2016 Elsevier B.V. All rights reserved.

引用

页码：1092 / 1102

页数：11

共 119 条

[11]

BRADLEY G, 1992, CANCER RES, V52, P5154

[12]

Bull V. L., 1988, STUDIES MODE CYTOTOX

[13] Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery [J].

Calvo, P ;

Gouritin, B ;

Chacun, H ;

Desmaële, D ;

D'Angelo, J ;

Noel, JP ;

Georgin, D ;

Fattal, E ;

Andreux, JP ;

Couvreur, P .

PHARMACEUTICAL RESEARCH, 2001, 18 (08) :1157-1166

[14] Modern methods for delivery of drugs across the blood-brain barrier [J].

Chen, Yan ;

Liu, Lihong .

ADVANCED DRUG DELIVERY REVIEWS, 2012, 64 (07) :640-665

[15] Nanostructured lipid carriers based temozolomide and gene co-encapsulated nanomedicine for gliomatosis cerebri combination therapy [J].

Chen, Zhihua ;

Lai, Xianliang ;

Song, Shuxin ;

Zhu, Xingen ;

Zhu, Jianming .

DRUG DELIVERY, 2016, 23 (04) :1369-1373

[16] Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat [J].

Cheng, Du ;

Cao, Nuo ;

Chen, Jifeng ;

Yu, Xingsu ;

Shuai, Xintao .

BIOMATERIALS, 2012, 33 (04) :1170-1179

[17] Visualizing Dynamics of Sub-Hepatic Distribution of Nanoparticles Using Intravital Multiphoton Fluorescence Microscopy [J].

Cheng, Shih-Hsun ;

Li, Feng-Chieh ;

Souris, Jeffrey S. ;

Yang, Chung-Shi ;

Tseng, Fan-Gang ;

Lee, Hsuan-Shu ;

Chen, Chin-Tu ;

Dong, Chen-Yuan ;

Lo, Leu-Wei .

ACS NANO, 2012, 6 (05) :4122-4131

[18] Comprehensive genomic characterization defines human glioblastoma genes and core pathways [J].

Chin, L. ;

Meyerson, M. ;

Aldape, K. ;

Bigner, D. ;

Mikkelsen, T. ;

VandenBerg, S. ;

Kahn, A. ;

Penny, R. ;

Ferguson, M. L. ;

Gerhard, D. S. ;

Getz, G. ;

Brennan, C. ;

Taylor, B. S. ;

Winckler, W. ;

Park, P. ;

Ladanyi, M. ;

Hoadley, K. A. ;

Verhaak, R. G. W. ;

Hayes, D. N. ;

Spellman, Paul T. ;

Absher, D. ;

Weir, B. A. ;

Ding, L. ;

Wheeler, D. ;

Lawrence, M. S. ;

Cibulskis, K. ;

Mardis, E. ;

Zhang, Jinghui ;

Wilson, R. K. ;

Donehower, L. ;

Wheeler, D. A. ;

Purdom, E. ;

Wallis, J. ;

Laird, P. W. ;

Herman, J. G. ;

Schuebel, K. E. ;

Weisenberger, D. J. ;

Baylin, S. B. ;

Schultz, N. ;

Yao, Jun ;

Wiedemeyer, R. ;

Weinstein, J. ;

Sander, C. ;

Gibbs, R. A. ;

Gray, J. ;

Kucherlapati, R. ;

Lander, E. S. ;

Myers, R. M. ;

Perou, C. M. ;

McLendon, Roger .

NATURE, 2008, 455 (7216) :1061-1068

[19] Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations [J].

Chinot, OL ;

Barrie, M ;

Frauger, E ;

Dufour, H ;

Figarella-Branger, D ;

Palmari, J ;

Braguer, D ;

Hoang-Xuan, K ;

Moktari, K ;

Peragut, JCC ;

Martin, PMM ;

Grisoli, F .

CANCER, 2004, 100 (10) :2208-2214

[20] FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme [J].

Cohen, Martin H. ;

Shen, Yuan Li ;

Keegan, Patricia ;

Pazdur, Richard .

ONCOLOGIST, 2009, 14 (11) :1131-1138

← 1 2 3 4 5 6 7 8 9 10 →